Online inquiry

IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5978MR)

This product GTTS-WQ5978MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5978MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2773MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ4740MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ8944MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ6515MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ404MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ5158MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ10771MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ7103MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW